Physician profile
Frances Lawhead
NPI 1992927214
$8,804.81
in general payments reported to CMS, 2019-2025
29 companies · $1,726 in 2025
The $1,726 reported for 2025 was more than what 83% of Dermatopathology (Dermatology) providers received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $967 · 2020: $171 · 2021: $790 · 2022: $1,412 · 2023: $1,915 · 2024: $1,823 · 2025: $1,726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,028 · Education: $436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,028.19 |
| Education | $436.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,789.53 | 2019-2025 | |
| Janssen Biotech, INC. | $1,342.03 | 2019-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $1,037.04 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,017.15 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $813.73 | 2021-2025 | Ilumya, Winlevi |
| Regeneron Healthcare Solutions, INC. | $557.07 | 2019-2025 | Dupixent |
| Leo Pharma INC. | $360.58 | 2019-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $352.53 | 2019-2025 | Taltz, Ebglyss |
| Pfizer INC. | $197.01 | 2019-2025 | |
| Incyte Corporation | $179.47 | 2024-2025 | Opzelura |
| Organogenesis INC. | $159.21 | 2021-2025 | Nushield, Puraply |
| Arcutis Biotherapeutics, INC. | $128.54 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $104.21 | 2022-2025 | Sotyktu |
| Celgene Corporation | $101.79 | 2019 | |
| Sanofi-Aventis U.S. LLC | $99.00 | 2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $85.98 | 2019-2025 | Nemluvio |
| Genentech USA, INC. | $75.74 | 2019-2022 | |
| Ucb, INC. | $69.71 | 2021-2025 | Cimzia, Bimzelx |
| Kerecis Limited | $64.85 | 2022-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Misonix INC | $50.71 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.57 | 2024-2025 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $37.52 | 2020-2023 | Jublia, Arazlo |
| Hydrofera LLC | $26.34 | 2024 | Hydrofera Blue |
| Organon LLC | $24.54 | 2025 | |
| Biofrontera INC. | $21.67 | 2021-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Botanix Sb INC | $19.35 | 2025 | Sofdra |
| Dermira, INC. | $19.30 | 2019 | |
| Blueprint Medicines Corporation | $15.33 | 2023 | |
| Mayne Pharma Commercial LLC | $12.31 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frances Lawhead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.